E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Acute myeloid lymphoma (AML), myelodysplastic syndrome (MDS), or solid tumors |
Leucemia mieloide aguda (LMA), síndromes mielodisplásicos (SMD), o tumores sólidos |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10000880 |
E.1.2 | Term | Acute myeloid leukaemia |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10028533 |
E.1.2 | Term | Myelodysplastic syndrome |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10065252 |
E.1.2 | Term | Solid tumor |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To provide ongoing long-term treatment with ASTX727 for subjects who were benefitting from ASTX727 treatment in a previous Astex-sponsored clinical study. |
Proporcionar tratamiento a largo plazo con ASTX727 a los pacientes que estuvieran obteniendo un beneficio del tratamiento con ASTX727 en un estudio clínico previo promovido por Astex |
|
E.2.2 | Secondary objectives of the trial |
To obtain information on survival and disease status, including conversion to AML (subjects with hematological malignancy only). |
Obtener información sobre la supervivencia y el estado de la enfermedad, incluida la conversión a LMA (solo pacientes con neoplasia maligna hematológica) |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1) Previous participation in an Astex-sponsored ASTX727 clinical trial (including but not limited to studies ASTX727-01, ASTX727-02, ASTX727-04, ASTX727-17, ASTX727-18) in which the subject was treated with ASTX727 and was still on active treatment with ASTX727 at the time of study completion as determined by Astex. 2) Subject is considered to be benefitting from ASTX727 treatment in the opinion of the treating investigator at the time of parent study completion. (Subjects must not be withdrawn from the parent study until eligibility for this study is confirmed.) 3) Subject is able to understand and comply with the study procedures and understands the risks involved in the study. 4) Subject provides legally effective informed consent before undergoing any study-specific procedure. 5) Women of childbearing potential (according to recommendations of the Clinical Trial Facilitation Group [CTFG]) must not be pregnant or breastfeeding and must have a negative pregnancy test at screening. Women of child-bearing potential must agree to practice 1 highly effective contraceptive measure of birth control with low user dependency and must agree not to become pregnant for 6 months after completing treatment. 6) Men with female partners of childbearing potential must agree to use a male condom and advise his partner to practice 1 highly effective contraceptive measure (user dependent or with low user dependency) while receiving treatment with ASTX727 for at least 3 months after completing treatment and must agree not to father a child while receiving study treatment for at least 3 months after completing ASTX727 treatment. |
1) Participación previa en un estudio clínico de ASTX727 promovido por Astex (incluidos, entre otros, los estudios ASTX727-01, ASTX727-02, ASTX727-04, ASTX727-17, ASTX727-18) donde el paciente recibía ASTX727 y seguía recibiéndolo en el momento de finalización del estudio, de acuerdo con la determinación de Astex. 2) En opinión del investigador responsable del tratamiento, el paciente seguía beneficiándose del tratamiento con ASTX727 en el momento de la finalización del estudio principal. (No se debe retirar a los pacientes del estudio principal hasta que se haya confirmado la elegibilidad para participar en este estudio). 3) El paciente es capaz de entender y cumplir los procedimientos del estudio y comprende los riesgos que este implica. 4) El paciente otorga el consentimiento informado con validez legal antes de realizar cualquier procedimiento específico del estudio. 5) Las mujeres con capacidad de concebir (de acuerdo con las recomendaciones del Clinical Trial Facilitation Group [CTFG])no deben estar embarazadas ni en periodo de lactancia y deben tener un resultado negativo en la prueba de embarazo en la selección. Las mujeres con capacidad de concebir deben comprometerse a utilizar 1 método anticonceptivo muy eficaz con baja dependencia del usuario y aceptar no quedarse embarazadas en los 6 meses posteriores a la finalización del tratamiento. 6) Los varones cuya pareja sea una mujer con capacidad de concebir deben comprometerse a utilizar preservativo masculino y aconsejar a su pareja que utilice 1 método anticonceptivo muy eficaz (dependiente del usuario o con baja dependencia del usuario), así como aceptar no concebir un hijo mientras estén recibiendo tratamiento con ASTX727 ni, como mínimo, en los 3 meses posteriores a la finalización del tratamiento. |
|
E.4 | Principal exclusion criteria |
1) Any subject who, in the opinion of the investigator, may have other conditions or for whom safety data from parent study participation suggests the risks of continuing treatment with ASTX727 may outweigh the benefits. |
1) Cualquier paciente que, en opinión del investigador, pueda tener otra enfermedad o cuyos datos de seguridad obtenidos durante el estudio principal indiquen que los riesgos de continuar el tratamiento con ASTX727 podrían superar los beneficios. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Safety as measured by AEs |
Seguridad determinada por los AA |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
AE monitoring - Day 1 of each cycle and at Safety Follow-up |
Monitorización de los AA - Día 1 de cada ciclo y seguimiento de seguridad |
|
E.5.2 | Secondary end point(s) |
Survival and disease status, including conversion to AML (subjects with hematological malignancy only). |
Supervivencia y estado de la enfermedad, incluida la conversión a LMA (solo pacientes con neoplasia maligna hematológica) |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Survival and disease status assessment - quaterly until death or until subject withdrawal from the study |
Evaluación de la supervivencia y estado de la enfermedad - trimestralmente hasta la muerte o hasta que el paciente sea retirado del estudio. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 4 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 13 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Canada |
Russian Federation |
United States |
European Union |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 20 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |